Protagonist Therapeutics Inc
$ 145.87
-0.21%
07 Aug - close price
- Market Cap 9,459,057,000 USD
- Current Price $ 145.87
- High / Low $ 147.32 / 144.44
- Stock P/E N/A
- Book Value 10.21
- EPS -1.93
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.12 %
- ROE -0.17 %
- 52 Week High 148.00
- 52 Week Low 50.58
About
Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical needs. The company is headquartered in Newark, California.
Analyst Target Price
$150.54
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-05 | 2026-05-05 | 2026-02-25 | 2025-11-06 | 2025-08-06 | 2025-05-06 | 2025-02-21 | 2024-11-07 | 2024-08-06 | 2024-05-07 | 2024-02-27 | 2023-11-02 |
| Reported EPS | 2.29 | 0.05 | -0.69 | -0.62 | -0.55 | -0.19 | 1.98 | -0.54 | -0.5 | 3.26 | 0.44 | -0.58 |
| Estimated EPS | 2.11 | -0.65 | -0.3403 | -0.64 | -0.52 | 0.11 | 0.25 | -0.53 | -0.41 | 1.6 | -0.03 | -0.7 |
| Surprise | 0.18 | 0.7 | -0.3497 | 0.02 | -0.03 | -0.3 | 1.73 | -0.01 | -0.09 | 1.66 | 0.47 | 0.12 |
| Surprise Percentage | 8.5308% | 107.6923% | -102.7623% | 3.125% | -5.7692% | -272.7273% | 692% | -1.8868% | -21.9512% | 103.75% | 1566.6667% | 17.1429% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PTGX
2026-08-07 07:31:50
Bank of America Corp DE significantly increased its stake in Protagonist Therapeutics, Inc. by 49.3% in the first quarter, now holding 1.30 million shares valued at approximately $136.5 million. This move is part of a broader trend where institutional investors and hedge funds own 98.63% of the company's stock. Despite positive analyst ratings and strong quarterly earnings, company insiders have recently sold a substantial number of shares.
2026-08-06 20:09:50
Citigroup has raised its price target for Protagonist Therapeutics (NASDAQ:PTGX) to $175 from $130, maintaining a "buy" rating and implying a 19.78% upside. The company recently exceeded quarterly earnings expectations, reporting $2.29 EPS against $2.24 expected, and revenues of $213.47 million. Despite positive analyst sentiment and strong institutional investment, insider selling totaling $11.55 million occurred last quarter.
2026-08-06 16:42:43
Barclays has maintained an "Overweight" rating on Protagonist Therapeutics (PTGX), increasing its price target to $153 from $151. Despite this cautious optimism from analysts, Protagonist Therapeutics is considered significantly overvalued with a GF Value of $72.54 against its current price of $144.87, and insider activity shows substantial selling. The company's GF Score of 47/100 highlights strong financial strength but weak profitability and growth, suggesting investors should proceed with caution.
2026-08-06 13:42:42
Protagonist Therapeutics (PTGX) stock reached an all-time high of $143.43, marking a 155% 1-year return. Despite an $8.83 billion market cap, InvestingPro suggests the stock may be overvalued relative to its Fair Value. Analysts project significant revenue growth and profitability by 2026, with several firms raising price targets due to strong performance and product potential like Icotyde.
2026-08-06 02:42:42
Citigroup has raised its target price for Protagonist Therapeutics, Inc. to $175 from $130. This update indicates a significant increase in the analyst's valuation of the company. The article, sourced from Reuters, briefly notes this financial adjustment.
2026-08-05 21:42:42
Protagonist Therapeutics, Inc. has released its earnings summary for the quarter that concluded on June 30. The report is available on TradingView, sourced from Refinitiv and Reuters.
